{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:18:37Z","timestamp":1780514317615,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s40261-021-01011-y","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T18:04:33Z","timestamp":1614967473000},"page":"321-339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Overall Efficacy and Safety of Safinamide in Parkinson\u2019s Disease: A Systematic Review and a Meta-analysis"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-9445","authenticated-orcid":false,"given":"Riccardo","family":"Giossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Mazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lo Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azzurra","family":"Schicchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Corr\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica Andrea","family":"Fittipaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Pani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Tramacere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Emanuele","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"1011_CR1","first-page":"901","volume-title":"Epidemiology of Parkinson\u2019s disease","author":"OB Tysnes","year":"2017","unstructured":"Tysnes OB, Storstein A. Epidemiology of Parkinson\u2019s disease. Wien: Springer; 2017. p. 901\u201315."},{"issue":"s1","key":"1011_CR2","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloem BR. The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis. 2018;8(s1):S3\u2013S8. https:\/\/doi.org\/10.3233\/JPD-181474.","journal-title":"J Parkinsons Dis."},{"key":"1011_CR3","unstructured":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet (London, England). 2017;390:1211\u201359."},{"key":"1011_CR4","doi-asserted-by":"crossref","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. Lancet Publishing Group; 2015. p. 896\u2013912.","DOI":"10.1016\/S0140-6736(14)61393-3"},{"issue":"11","key":"1011_CR5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/nrd.2018.136","volume":"17","author":"D Charvin","year":"2018","unstructured":"Charvin D, Medori R, Hauser RA, Rascol O. Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018;17(11):804\u201322. https:\/\/doi.org\/10.1038\/nrd.2018.136.","journal-title":"Nat Rev Drug Discov."},{"key":"1011_CR6","first-page":"1670","volume-title":"Lang AE","author":"BS Connolly","year":"2014","unstructured":"Connolly BS. Lang AE. Pharmacological treatment of Parkinson disease: A review. JAMA - J. Am. Med. Assoc. American Medical Association; 2014. p. 1670\u201383."},{"key":"1011_CR7","doi-asserted-by":"crossref","unstructured":"Jenner P. Molecular mechanisms of l-DOPA-induced dyskinesia. Nat Rev Neurosci. 2008. p. 665\u201377.","DOI":"10.1038\/nrn2471"},{"issue":"8","key":"1011_CR8","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.parkreldis.2007.06.015","volume":"13","author":"P Riederer","year":"2007","unstructured":"Riederer P, Gerlach M, M\u00fcller T, Reichmann H. Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. Parkinsonism Relat Disord. 2007;13(8):466\u201379. https:\/\/doi.org\/10.1016\/j.parkreldis.2007.06.015.","journal-title":"Parkinsonism Relat Disord."},{"key":"1011_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.phrs.2003.12.004","volume":"50","author":"A Marzo","year":"2004","unstructured":"Marzo A, Dal Bo L, Monti NC, Crivelli F, Ismaili S, Caccia C, et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res. 2004;50:77\u201385.","journal-title":"Pharmacol Res"},{"issue":"3","key":"1011_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40262-016-0449-5","volume":"56","author":"T M\u00fcller","year":"2017","unstructured":"M\u00fcller T, Foley P. Clinical Pharmacokinetics and Pharmacodynamics of Safinamide. Clin Pharmacokinet. 2017;56(3):251\u201361. https:\/\/doi.org\/10.1007\/s40262-016-0449-5.","journal-title":"Clin Pharmacokinet."},{"issue":"10","key":"1011_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/CPAA.S137740","volume":"5","author":"T M\u00fcller","year":"2018","unstructured":"M\u00fcller T. Safinamide: an add-on treatment for managing Parkinson's disease. Clin Pharmacol. 2018;10:31\u201341. https:\/\/doi.org\/10.2147\/CPAA.S137740.","journal-title":"Clin Pharmacol."},{"issue":"5","key":"1011_CR12","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.parkreldis.2013.01.009","volume":"19","author":"L Gr\u00e9goire","year":"2013","unstructured":"Gr\u00e9goire L, Jourdain VA, Townsend M, Roach A, Di Paolo T. Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord. 2013;19(5):508\u201314. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.01.009.","journal-title":"Parkinsonism Relat Disord."},{"key":"1011_CR13","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1111\/bcp.13651","volume":"84","author":"CD Binde","year":"2018","unstructured":"Binde CD, Tvete IF, Gasemyr J, Natvig B, Klemp M. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson\u2019s disease. Br J Clin Pharmacol. 2018;84:1917\u201327.","journal-title":"Br J Clin Pharmacol."},{"key":"1011_CR14","volume-title":"Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson\u2019s disease: a multiple treatment comparison meta-analysis","author":"CD Binde","year":"2020","unstructured":"Binde CD, Tvete IF, G\u00e5semyr JI, Natvig B, Klemp M. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson\u2019s disease: a multiple treatment comparison meta-analysis. Germany: Eur J Clin Pharmacol; 2020."},{"key":"1011_CR15","first-page":"S101","volume":"33","author":"S Hussain","year":"2018","unstructured":"Hussain S, Najimi A. Efficacy and safety of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a systematic review of randomized controlled trials. Mov Disord. 2018;33:S101.","journal-title":"Mov Disord."},{"key":"1011_CR16","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim S-Y, Barton B, de Bie RMA, Seppi K, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2018;33:1248\u201366.","journal-title":"Mov Disord."},{"key":"1011_CR17","unstructured":"Abdelalem Aziz Ahmed M. A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson\u2019s disease. F1000Research. F1000 Research Ltd; 2019;8:2078."},{"key":"1011_CR18","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/mds.20248","volume":"19","author":"RA Hauser","year":"2004","unstructured":"Hauser RA, Deckers F, Lehert P. Parkinson\u2019s disease home diary: further validation and implications for clinical trials. Mov Disord. 2004;19:1409\u201313.","journal-title":"Mov Disord."},{"key":"1011_CR19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ."},{"key":"1011_CR20","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/mds.870090403","volume":"9","author":"CG Goetz","year":"1994","unstructured":"Goetz CG, Stebbins GT, Shale HM, Lang AE, Chernik DA, Chmura TA, et al. Utility of an objective dyskinesia rating scale for Parkinson\u2019s disease: Inter- and intrarater reliability assessment. Mov Disord. 1994;9:390\u20134.","journal-title":"Mov Disord."},{"key":"1011_CR21","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1002\/mds.22341","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskinesia Rating Scale: Presentation and Clinimetric Profile. Mov Disord. 2008;23:2398\u2013403.","journal-title":"Mov Disord."},{"key":"1011_CR22","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group; 2013."},{"key":"1011_CR23","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","volume":"365","author":"O Rascol","year":"2005","unstructured":"Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365:947\u201354.","journal-title":"Lancet"},{"key":"1011_CR24","doi-asserted-by":"publisher","unstructured":"Hauser RA, Auinger P. Determination of minimal clinically important change in early and advanced Parkinson\u2019s disease. Mov Disord [Internet]. 2011 [cited 2020 Mar 14];26:813\u20138. https:\/\/doi.org\/10.1002\/mds.23638.","DOI":"10.1002\/mds.23638"},{"key":"1011_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/archneurol.2009.295","volume":"67","author":"LM Shulman","year":"2010","unstructured":"Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the unified Parkinson\u2019s Disease Rating Scale. Arch Neurol. 2010;67:64\u201370.","journal-title":"Arch Neurol"},{"key":"1011_CR26","doi-asserted-by":"crossref","unstructured":"Pahwa R, Tanner C, Hauser R, Isaacson S, Johnson R, Felt L, et al. A clinically important difference (CID) for the Unified Dyskinesia Rating Scale (UDysRS) Total Score Change in Parkinson\u2019s Disease (PD) Patients with Dyskinesia (P2.052). Neurology. 2018;90 (15 Sup).","DOI":"10.1212\/WNL.90.15_supplement.P2.052"},{"key":"1011_CR27","unstructured":"Peto V, Jenkinson C, Fitzpatrick R. Determining minimally important differences for the PDQ-39 Parkinson\u2019s disease questionnaire."},{"key":"1011_CR28","doi-asserted-by":"publisher","unstructured":"Stocchi F, Arnold G, Onofrj M, Kwiecinski H, Szczudlik A, Thomas A, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology [Internet]. 2004;63:746\u20138. https:\/\/www.cochranelibrary.com\/central\/. https:\/\/doi.org\/10.1002\/central\/CN-00504635\/full.","DOI":"10.1002\/central\/CN-00504635\/full"},{"issue":"4","key":"1011_CR29","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1212\/01.wnl.0000134672.44217.f7","volume":"63","author":"F Stocchi","year":"2004","unstructured":"Stocchi F, Arnold G, Onofrj M, Kwiecinski H, Szczudlik A, Thomas A, Bonuccelli U, Van Dijk A, Cattaneo C, Sala P, Fariello RG; Safinamide Parkinson's Study Group. Improvement of motor function in early Parkinson disease by safinamide. Neurology. 2004;63(4):746\u20138. https:\/\/doi.org\/10.1212\/01.wnl.0000134672.44217.f7.","journal-title":"Neurology."},{"issue":"2","key":"1011_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mds.25751","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R; Study 016 Investigators. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord. 2014;29(2):229\u201337. https:\/\/doi.org\/10.1002\/mds.25751.","journal-title":"Mov Disord."},{"key":"1011_CR31","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","volume":"74","author":"AH Schapira","year":"2017","unstructured":"Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74:216\u201324.","journal-title":"JAMA Neurol."},{"key":"1011_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.parkreldis.2020.04.012","volume":"75","author":"N Hattori","year":"2020","unstructured":"Hattori N, Tsuboi Y, Yamamoto A, Sasagawa Y, Nomoto M. Efficacy and safety of safinamide as an add-on therapy to l-DOPA for patients with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled, phase II\/III study. Parkinsonism Relat Disord. 2020;75:17\u201323.","journal-title":"Parkinsonism Relat Disord"},{"key":"1011_CR33","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Assessment report Xadago. 2014. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xadago. Accessed 26 Feb 2021."},{"key":"1011_CR34","unstructured":"U.S. Food and Drug Administrastion. Xadago (safinamide) Tablets [Internet]. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/207145Orig1s000TOC.cfm. Accessed 6 Mar 2020."},{"key":"1011_CR35","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1468-1331.2012.03840.x","volume":"20","author":"AH Schapira","year":"2013","unstructured":"Schapira AH, Stocchi F, Borgohain R, Onofrj M, Bhatt M, Lorenzana P, et al. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson\u2019s disease. Eur J Neurol. 2013;20:271\u201380.","journal-title":"Eur J Neurol."},{"key":"1011_CR36","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/mds.25961","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease. Mov Disord. 2014;29:1273\u201380.","journal-title":"Mov Disord."},{"key":"1011_CR37","doi-asserted-by":"crossref","unstructured":"M\u00ednguez-M\u00ednguez S, Del Pozo JSG, Jord\u00e1n J. Rasagiline in Parkinson\u2019s disease: A review based on meta-analysis of clinical data. Pharmacol. Res. 2013 p. 78\u201386.\u00a0","DOI":"10.1016\/j.phrs.2013.05.005"},{"key":"1011_CR38","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/07853890.2017.1293285","volume":"49","author":"Y Chang","year":"2017","unstructured":"Chang Y, Wang LB, Li D, Lei K, Liu SY. Efficacy of rasagiline for the treatment of Parkinson\u2019s disease: an updated meta-analysis. Ann Med. 2017;49:421\u201334.","journal-title":"Ann Med"},{"key":"1011_CR39","doi-asserted-by":"publisher","first-page":"117012","DOI":"10.1016\/j.jns.2020.117012","volume":"416","author":"Y Tsuboi","year":"2020","unstructured":"Tsuboi Y, Hattori N, Yamamoto A, Sasagawa Y, Nomoto M. Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson\u2019s disease with wearing-off: results of an open-label study. J Neurol Sci. 2020;416:117012.","journal-title":"J Neurol Sci"},{"key":"1011_CR40","doi-asserted-by":"crossref","unstructured":"Abbruzzese G, Kulisevsky J, Bergmans B, Gomez-Esteban JC, K\u00e4gi G, Raw J, Stefani A, Warnecke T, Jost WH; SYNAPSES Study Investigators Group. A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. J Parkinsons Dis. 2021;11(1):187\u201398.","DOI":"10.3233\/JPD-202224"},{"key":"1011_CR41","unstructured":"Impact of safinamide on non-motor and motor experiences of daily living: Primary results from the prospective, observational ProGo study\u2014MDS Abstracts.\u00a0https:\/\/www.mdsabstracts.org\/abstract\/impact-of-safinamide-on-non-motor-and-motor-experiences-of-daily-living-primary-results-from-the-prospective-observational-progo-study\/. Accessed 19 Jan 2021."},{"key":"1011_CR42","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/mds.25321","volume":"28","author":"CG Goetz","year":"2013","unstructured":"Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, et al. Which dyskinesia scale best detects treatment response? Mov Disord. 2013;28:341\u20136.","journal-title":"Mov Disord."},{"key":"1011_CR43","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129\u201370.","journal-title":"Mov Disord"},{"issue":"13","key":"1011_CR44","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","volume":"361","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361(13):1268\u201378.","journal-title":"N Engl J Med."},{"key":"1011_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004898.pub2","author":"K Turnbull","year":"2005","unstructured":"Turnbull K, Caslake R, Macleod A, Ives N, Stowe R, Counsell C. Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev. 2005. https:\/\/doi.org\/10.1002\/14651858.CD004898.pub2.","journal-title":"Cochrane Database Syst Rev."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01011-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-021-01011-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01011-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T12:46:26Z","timestamp":1724589986000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-021-01011-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1011"],"URL":"https:\/\/doi.org\/10.1007\/s40261-021-01011-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]},"assertion":[{"value":"5 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Milano within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Riccardo Giossi reports non-financial support for congress participation from Mylan, outside the submitted work. Prof. Francesco Scaglione reports grants from Pfizer, lecture fees from Novartis and MSD, and has served on advisory board for GSK, outside the submitted work. Other authors declare no financial or other conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"R.G. contributed to study conception and design, data acquisition, analysis and interpretation, and paper drafting. F.C., M.M., F.L.R., M.S., A.S., F.C. contributed to data acquisition and analysis. V.A.F. contributed to study design and data acquisition. A.P. gave critical revision for intellectual content. I.T. contributed to data analysis and interpretation, paper drafting, and gave critical revision. A.E.E. contributed to data interpretation, paper drafting, and gave critical revision for intellectual content. F.S. gave critical revision for intellectual content.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"None.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}}]}}